Abstract

Lapatinib is a small-molecule kinase inhibitor that targets the epidermal growth factor receptor and the human epidermal growth factor receptor 2 (HER2). In March 2007, lapatinib distosylate monohydrate (Tykerb; GlaxoSmithKline) was approved by the FDA for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab.

Author affiliations

1. Beverly Moy and Paul Goss are at the Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA.
   Email: bmoy@partners.org
   Email: pgoss@partners.org
2. Santwana Kar is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.
   Email: skar@uk.imshealth.com
3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.
   Email: p.kirkpatrick@nature.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.